Want to see FR:CVX full AI Analyst Report?

Affluent Medical SA (CVX) Price & Analysis

2 Followers

CVX Stock Chart & Stats

€5.56

€0.14(2.52%)

At close: Jul 27 4:00 PM EDT

€5.56

€0.14(2.52%)

Day’s Range― - ―

52-Week Range€1.18 - €7.56

Previous CloseN/A

Volume20.00K

Average Volume (3M)9.49K

Market Cap

€348.57M

Enterprise Value€164.42M

Total Cash (Recent Filing)€1.76M

Total Debt (Recent Filing)€24.04M

Price to Earnings (P/E)―

Beta0.46

Next Earnings

Sep 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.64

Shares Outstanding62,269,176

10 Day Avg. Volume9,769

30 Day Avg. Volume9,492

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)12.26

Price to Sales (P/S)0.00

P/FCF Ratio-5.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€5.00

Price Target Upside-10.07% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.46

Revenue Forecast (FY)€1.96M

Bulls Say, Bears Say

Bulls Say

Diversified Device PipelineAffluent Medical runs multiple late-stage development programs across structural heart, vascular and urinary spheres. This diversification gives several independent commercialization pathways, lowering single-product binary risk and increasing chances of licensing or partnership outcomes over the next 2–6 months to years.

Substantial Asset BaseDespite equity erosion, the company retains a meaningful asset base that supports ongoing R&D and can serve as collateral or negotiating leverage in financing or M&A discussions. A tangible asset foundation improves optionality for partnerships or structured funding while trials progress.

Clear R&D-to-commercialization ModelThe firm’s business model is purpose-built for medtech value creation: clinical milestones and regulatory approvals drive de-risking and value inflection. This alignment with standard medtech commercialization routes makes the company a credible partner or licensee for larger medical device firms.

Bears Say

Zero Reported 2025 RevenueReporting no revenue in 2025 signals absence of internal cash generation and stalled commercialization progress. Over a multi-quarter horizon this raises dependence on external funding to sustain trials and operations, slowing pathway to self-sustaining growth and increasing execution risk.

Deteriorating Leverage And Equity ErosionRising debt alongside collapsing equity meaningfully reduces financial flexibility. Higher leverage increases refinancing and covenant risk, likely forcing dilutive capital raises or costly borrowing, which can impair long-term funding of clinical programs and weaken negotiating position with partners.

Persistent And Worsening Cash BurnConsistent negative operating and free cash flows show that losses translate into real cash outflows. Continued cash burn without revenue makes the company reliant on external financing to progress trials, elevating execution and dilution risk and threatening continuity if markets tighten.

Affluent Medical SA News

ODDO BHF Launches Outperformance Coverage on Carvolix, Signaling Strong Upside Potential

Affluent Medical SA ( ($FR:CVX) ) has shared an announcement. Carvolix has gained fresh attention in the equity...

2h ago

Affluent Medical Strengthens Leadership Team to Drive Market Access

Affluent Medical SA ( ($FR:AFME) ) has shared an announcement. Affluent Medical has announced key leadership appointments to...

1y ago

Affluent Medical Strengthens Board with Industry Veteran Liane Teplitsky

Affluent Medical SA ( ($FR:AFME) ) has issued an announcement. Affluent Medical has appointed Liane Teplitsky, a seasoned...

1y ago

Affluent Medical Discloses Share Capital and Voting Rights Details

An announcement from Affluent Medical SA ( ($FR:AFME) ) is now available. Affluent Medical has disclosed the number...

1y ago

Affluent Medical Completes Pilot Phase of Artus Urinary Sphincter Study

Affluent Medical SA ( ($FR:AFME) ) has issued an update. Affluent Medical has achieved a significant milestone by...

1y ago

Affluent Medical Reports Half-Year Liquidity Contract Update

Affluent Medical SA ( ($FR:AFME) ) just unveiled an announcement. Affluent Medical has released its half-year liquidity contract...

2y ago

Affluent Medical Announces Share and Voting Rights Details

Affluent Medical SA ( ($FR:AFME) ) just unveiled an update. Affluent Medical announced the total number of shares...

2y ago

Affluent Medical Enhances Share Liquidity with New Contract

Affluent Medical SA (FR:AFME) has released an update. Affluent Medical has initiated a new liquidity contract with Rothschild...

2y ago

Affluent Medical SA Gears Up for Scientific Showcases

Affluent Medical SA (FR:AFME) has released an update. Affluent Medical SA, a French medical technology company, is set...

2y ago

Affluent Medical Targets 2026 Market Entry

Affluent Medical SA (FR:AFME) has released an update. Affluent Medical, a French medtech firm, has detailed its share...

2y ago

CVX FAQ

What was Affluent Medical SA’s price range in the past 12 months?

Affluent Medical SA lowest stock price was €1.18 and its highest was €7.56 in the past 12 months.

What is Affluent Medical SA’s market cap?

Affluent Medical SA’s market cap is €348.57M.

When is Affluent Medical SA’s upcoming earnings report date?

Affluent Medical SA’s upcoming earnings report date is Sep 24, 2026 which is in 57 days.

How were Affluent Medical SA’s earnings last quarter?

Currently, no data Available

Is Affluent Medical SA overvalued?

According to Wall Street analysts Affluent Medical SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Affluent Medical SA pay dividends?

Affluent Medical SA does not currently pay dividends.

What is Affluent Medical SA’s EPS estimate?

Affluent Medical SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Affluent Medical SA have?

Affluent Medical SA has 62,269,176 shares outstanding.

What happened to Affluent Medical SA’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Affluent Medical SA?

Currently, no hedge funds are holding shares in FR:CVX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Affluent Medical SA

Carvolix S.A. operates as a medical technology firm, concurrently involved in both commercialization and clinical development, specializing in treatment solutions for structural heart ailments and cerebral strokes. The company's innovative endeavors encompass the creation of AI- and imaging-driven mini-robots, engineered for executing intricate medical procedures, as well as the development of biomimetic heart valves. Established on January 30, 2026, Carvolix S.A. maintains its headquarters in Aix-en-Provence, France.

Affluent Medical SA (CVX) Earnings & Revenues

Historic Earnings Reports

CVX Stock 12 Month Forecast

Average Price Target

€5.00

▼(-10.07% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","3":"€3","6":"€6","1.5":"€1.5","4.5":"€4.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.5,3,4.5,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.4,3.523076923076923,3.646153846153846,3.769230769230769,3.8923076923076922,4.015384615384615,4.138461538461538,4.2615384615384615,4.384615384615385,4.507692307692308,4.63076923076923,4.753846153846154,4.876923076923077,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.4,3.523076923076923,3.646153846153846,3.769230769230769,3.8923076923076922,4.015384615384615,4.138461538461538,4.2615384615384615,4.384615384615385,4.507692307692308,4.63076923076923,4.753846153846154,4.876923076923077,{"y":5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.4,3.523076923076923,3.646153846153846,3.769230769230769,3.8923076923076922,4.015384615384615,4.138461538461538,4.2615384615384615,4.384615384615385,4.507692307692308,4.63076923076923,4.753846153846154,4.876923076923077,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.27,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.545,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.545,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.73,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.83,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.67,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >